Drug	Sponsor	Target	Indications	Major toxicities	Black box warning(s)	MS	D	FR	PC (AU)	PC (US)	FDA AD
Afatinib	Boehringer Ingelheim	EGFR, ErbB family (irreversible)	Advanced non-small cell lung cancer	Hepatotoxicity, kidney failure, electrolyte anomalies (mostly hypokalaemia) and interstitial lung disease (uncommon).	None	-	+++	-	C	D	12 July 2013
Aflibercept	Bayer, Regeneron	VEGF	Advanced colorectal cancer and wet macular degeneration.	GI perforation, haemorrhage and hepatotoxicity	None	+++/++	+++/++	-	D	C	21 November 2011
Axitinib	Pfizer	VEGFR, PDGFR, c-KIT	Renal cell carcinoma	Thyroid dysfunction, blood clots, haemorrhages, reversible posterior leucoencephalopathy syndrome (uncommon), GI perforation/fistula (uncommon) and electrolyte disturbances	None	++	++	-	D	D	27 January 2012
Bevacizumab	Genentech	VEGF	Colorectal cancer, breast cancer, non-small cell lung cancer, renal cell carcinoma, macular degeneration and glioblastoma	Hypertension, GI perforation, ovarian failure, GI haemorrhage, blood clots, electrolyte anomalies, ileus, congestive heart failure, osteonecrosis of the jaw (rare), necrotising fasciitis (rare), gallbladder perforation (rare)	GI perforation, haemorrhage and wound healing complications	++	++/+	-	D	C	26 February 2004
Bosutinib	Pfizer	Bcr-Abl, Src, Lyn, Hck	Second-line Chronic myelogenous leukaemia treatment	Lower respiratory tract infection, anaphylaxis (uncommon), electrolyte anomalies, cardiovascular effects (especially QT interval prolongation), GI haemorrhage (uncommon), hepatotoxicity and kidney failure.	None	++/+	+++	+	N/A	D	4 September 2012
Cabozantinib	Exelixis	RET, Met, VEGFR, Kit, TrkB, FLT3, AXL, TIE2	Metastatic thyroid cancer	Electrolyte anomalies, hypotension, peripheral sensory neuropathy, GI perforation/fistula, reversible posterior leucoencephalopathy syndrome (rare), blood clots and osteonecrosis.	GI haemorrhage, perforation and fistula	++	+++/++	-	N/A	D	29 November 2012
Crizotinib	Pfizer	ALK, HGFR, c-MET, ROS	Anaplastic lymphoma kinase-positive non-small cell lung cancer	Peripheral neuropathy, electrolyte anomalies, blood clots, kidney cyst, liver failure, interstitial lung disease and cardiotoxicity (probably QT interval prolongation).	None	++	++	++/+	D	D	26 August 2011
Dasatinib	Bristol-Myers Squibb	Bcr-Abl, Src, Lck, Yes, Fyn, KIT, EphA2, PDGFRbeta	Second-line Chronic myelogenous leukaemia treatment	Electrolyte disturbances, haemorrhages, fluid retention, heart failure (uncommon), myocardial infarction (uncommon) and pulmonary hypertension	None	+/-	++	++	D	D	28 June 2006
Erlotinib	Roche	EGFR	Advanced non-small cell lung cancer and pancreatic cancer	GI bleeds (rare), hepatic failure (rare), hepatorenal syndrome (rare), EGFR skin reactions and interstitial lung disease(uncommon).	None	-	+++/++	-	C	D	18 November 2004
Gefitinib	AstraZeneca, Teva	EGFR	Advanced non-small cell lung cancer with EGFR mutation	Haemorrhage, EGFR skin reactions (including Stevens-Johnson syndrome [SJS; rare] and toxic epidermal necrolysis[TEN; rare]), liver failure (rare), hepatitis (uncommon), pancreatitis (uncommon) and interstitial lung disease (uncommon).	N/A	-	+++/++	-	C	D	5 May 2003
Imatinib	Novartis	Bcr-Abl,Kit, PDGFR	First-line chronic myelogenous leukaemia treatment	Haemorrhage, electrolyte disturbances, cardiotoxicity (uncommon), kidney failure (uncommon), GI perforation, hepatotoxicity (rare) and rhabdomyolysis (rare)	N/A	+++/++	+	++	D	D	10 May 2003
Lapatinib	GlaxoSmithKline	HER2, ErbB2, EGFR	HER2-positive advanced breast cancer	Hypersensitivity (rare), hepatotoxicity (uncommon), interstitial lung disease (uncommon) and cardiovascular problems.	Hepatotoxicity	-	++	-	C	D	13 March 2007
Nilotinib	Novartis	Bcr-Abl, PDGFR	Second-line chronic myelogenous leukaemia treatment	Hyperglycaemia, electrolyte disturbances, fluid retention, pancreatitis and cardiotoxicity (mostly QT interval prolongation).	QT interval prolongation and electrolyte anomalies	++	+	+	D	D	29 October 2007
Panitumumab	Amgen	EGFR	Colorectal cancer	Electrolyte anomalies, anaphylaxis, blood clots, sepsis and pulmonary fibrosis.	Dermatologic reactions and infusion reactions	-	+	+	C	C	10 October 2006
Pazopanib	GlaxoSmithKline	VEGFR, PDGFR, c-KIT, FGFR, Lck, Fms, Itk	Renal cell carcinoma and soft tissue sarcoma	Cardiotoxicity (mostly QT interval prolongation but also heart failure [uncommon]), blood clots, haemorrhage, thyroid anomalies (mostly hypothyroidism), blood glucose anomalies (hypoglycaemia and hyperglycaemia), torsades de pointes (uncommon), hepatotoxicity (uncommon), GI perforation/fistula (uncommon) and reversible posterior leucoencephalopathy syndrome (rare).	Hepatotoxicity	-	++	-	D	D	19 October 2009
Pegaptanib	OSI, Pfizer	VEGF	Wet macular degeneration	Hypertension, cataracts, haemorrhage, vitreous floater, transient ischaemic attack, retinal detachment, diabetes mellitus and urinary tract infection	None	-	+/-	++	N/A	B	17 December 2004
Ponatinib	ARIAD Pharmaceuticals	Bcr-Abl, VEGFR, PDGFR, FGFR, EPH, SRC, c-KIT, RET, TIE2, FLT3	T315I-positive Chronic myelogenous leukaemia and T315I-positive-Acute lymphoblastic leukaemia	Hypertension, pneumonia, urinary tract infection, sepsis, GI haemorrhage, liver failure, cardiovascular problems and blood clots.	Liver failure, blood clots and hepatotoxicity	++	+	+	N/A	D	14 December 2012
Ranibizumab	Novartis	VEGF-A	Wet macular degeneration and macular oedema (including diabetic macular oedema)	Haemorrhage (conjunctival, vitreous and injection site), increased intraocular pressure, vitreous detachment and retinal degeneration.	None	-	-	-	D	C	10 August 2012
Regorafenib	Bayer	RET, VEGFR, PDGFR, Bcr-Abl, BRAF, KIT, FGFR, TIE2, EPH2A	Advanced colorectal cancer, gastrointestinal stromal tumours	Electrolyte anomalies, hepatotoxicity, hypotension, haemorrhage, GI fistula, thyroid problems and blood clots.	Hepatotoxicity	+++/++	++	-	D	D	27 September 2012
Ruxolitinib	Novartis	JAK	Myelofibrosis	Hypercholesterolaemia, urinary tract infection, herpes zoster, tuberculosis and hepatotoxicity	None	+++	-	-	C	C	16 November 2011
Sorafenib	Bayer	VEGFR, PDGFR, BRAF, CRAF, c-KIT, FLT3, RET.	Advanced Renal cell carcinoma and Hepatocellular carcinoma	Hypertension, peripheral neuropathy, thyroid dysfunction, cardiovascular problems (e.g. QT interval prolongation, heart attack or heart failure), electrolyte anomalies, GI perforation (uncommon), pancreatitis (uncommon), hepatitis (rare), nephrotic syndrome (rare) and reversible posterior leucoencephalopathy syndrome (rare)	None	++	++	-	D	D	20 December 2005
Sunitinib	Pfizer	VEGFR, PDGFR, KIT, FLT3, RET, CSF-1R	Renal cell carcinoma, GI stromal tumour, pancreatic neuroendocrine tumour	Blood clots, cardiovascular problems (mostly heart failure or left ventricular dysfunction but also QT interval prolongation and torsades de pointes), thyroid dysfunction, electrolyte anomalies, skin reactions (including SJS [rare] and TEN [rare]), liver failure (uncommon) and pancreatitis (uncommon).	Hepatotoxicity	+	++	+	D	D	26 January 2006
Tofacitinib	Pfizer	JAK3	Rheumatoid arthritis	Infections and malignancies	Serious infections and malignancies	-	-	-	N/A	C	6 November 2012
Trastuzumab	Genentech	HER2	Breast cancer (for either metastatic disease or adjuvant treatment), metastatic gastric cancer	Congestive heart failure, depression, pulmonary toxicity, infections and tachycardia (heart high rate)	Pulmonary toxicity, cardiomyopathy and a confusion warning	-	+	+	B2	D	25 September 1998
Vandetanib	AstraZeneca	VEGFR, EGFR, RET, BRK, TIE2, SRC, EPHR	Advanced medullary thyroid cancer	Urinary tract infection, hypertension, QT interval prolongation, electrolyte anomalies, depression, GI perforation and thyroid anomalies	QT interval prolongation	-	++	-	D	D	21 April 2011
Vemurafenib	Hoffmann-La Roche	ARAF, BRAF, CRAF	Metastatic malignant melanoma	Photosensitivity, squamous cell carcinoma and hepatotoxicity	None	-	+	+	D	D	17 August 2011
Ceritinib	Novartis	ALK, IGF-1R, ROS1, InsR	ALK-positive, Advanced non-small cell lung cancer after crizotinib resistance							2014
Dabrafenib	GlaxoSmithKline	BRAF	Melanoma							2013
Everolimus	Novartis	FKBP12/mTOR	Progressive neuroendocrine tumors of pancreatic origin, Renal cell carcinoma, subependymal giant cell astrocytoma, breast cancer						2009
Ibrutinib	Pharmacyclics, Johnson & Johnson	BTK	Mantle cell lymphoma, CLL						2013
Nintedanib	Boehringer Ingelheim	VEGFR, FGFR, PDGFR	Idiopathic pulmonary fibrosis							2014
Sirolimus	Pfizer	FKBP12/mTOR	Renal transplant							1999
Temsirolimus	Pfizer	FKBP12/mTOR	Renal cell carcinoma							2007
Trametinib	GlaxoSmithKline	MEK	Melanoma							2013

## Jänne, Pasi A.; Gray, Nathanael; Settleman, Jeff (2009). "Factors underlying sensitivity of cancers to small-molecule kinase inhibitors". Nature Reviews Drug Discovery 8(9):709–23. doi:10.1038/nrd2871. PMID 19629074
## http://www.brimr.org/PKI/PKIs.htm
